CDC recommends Doxycycline as preventative measure against STIs
Concerns about drug-resistant infections and impact on gut bacteria
Elevated risk periods for prevention
Use reduces risk of getting infection by up to 70% within 72 hours of exposure
A recent advisory from the Centers for Disease Control and Prevention (CDC) has recommended the use of antibiotics, specifically Doxycycline, to prevent sexually transmitted infections (STIs) rather than just treating them. This comes as cases of STIs such as gonorrhea, chlamydia, and syphilis have been on the rise in recent years. According to data from Lee County in Florida, there has been a significant increase in cases of these STIs between 2006 and 2022. The CDC endorsed the use of Doxycycline as a preventative measure for those who have unprotected sex, particularly men who have sex with men or transgender women. This antibiotic can reduce the risk of getting an infection by up to 70% if taken within 72 hours of exposure. The McGregor Clinic in Fort Myers, Florida has recently launched a new service to make this morning-after pill more accessible to those at risk.
The use of antibiotics as a preventative measure for STIs is not a new concept. Research has shown that doxycycline can significantly reduce cases of syphilis, gonorrhea, and chlamydia when taken every day. The CDC recommends this approach primarily for people at elevated risk during certain periods. However, there are concerns about the potential development of drug-resistant infections and the impact on healthy gut bacteria in people taking it every day.
The escalating crisis of sexually transmitted inctions has led scientists to explore new solutions. The approach of using antibiotics as a preventative measure is gaining attention, but more research is needed to confirm its effectiveness and safety. It's important for individuals to take control of their sexual health by being informed about the risks and available prevention options.
Experts are exploring the use of doxycycline, a common antibiotic, to prevent sexually transmitted infections (STIs) rather than just treating them.
,
Accuracy
Three randomized controlled trials found that providing doxycycline to gay and bisexual men and trans women reduced their risk of chlamydia, syphilis, and gonorrhea by more than 70%, 50%, and about 50% respectively.
A small Canadian study found that daily doxycycline reduced STI diagnosis rates by 68% to 92% for gay and bisexual men.
In Japan, a study involving female sex workers showed an 80 diagnoses rate per 100 cumulative years of follow-up after receiving doxycycline, with syphilis vanishing among them.
A study found that doxycycline, a common antibiotic, reduces cases of syphilis, gonorrhea and chlamydia when taken every day.
The C.D.C. recommends gay and bisexual men and transgender women at risk for S.T.I.'s to take doxycycline within 72 hours of unprotected sex.
Accuracy
Three randomized controlled trials found that providing doxycycline to gay and bisexual men and trans women reduced their risk of chlamydia, syphilis, and gonorrhea by more than 70%, 50%, and about 50% respectively.
Deception
(95%)
The article makes several statements that could be considered deceptive or misleading. The author states that 'scientists reported' a study found that doxycycline reduces cases of syphilis, gonorrhea and chlamydia when taken every day. However, the author does not provide any direct quotes or references to the actual study in question. This is an example of selective reporting as the author only reports details that support their position without providing a complete picture. Additionally, the author states that 'The approach would be recommended primarily to people at elevated risk of sexually transmitted infections during certain periods.' However, this statement is not backed up by any evidence or quotes from experts in the field. This is an example of editorializing and pontification as the author is expressing their opinion without providing any facts to support it.
scientists reported on Thursday that a common antibiotic, doxycycline, greatly reduced cases of syphilis, gonorrhea and chlamydia when taken every day
The approach would be recommended primarily to people at elevated risk of sexually transmitted inctions during certain periods
The author takes Pre-Exposure Prophylaxis (PrEP) and DoxyPEP for HIV prevention and bacterial STIs respectively.
DoxyPEP is not yet approved for use on the NHS in the UK but some clinics are considering making it available soon.
Accuracy
DoxyPEP can protect against 70-89% of chlamydia infections, 73-87% of syphilis infections, over 51-57% of gonorrhoea infections.
Three randomized controlled trials found that providing doxycycline to gay and bisexual men and trans women reduced their risk of chlamydia, syphilis, and gonorrhea by more than 70%, 50%, and about 50% respectively.
A study found that doxycycline, a common antibiotic, reduces cases of syphilis, gonorrhea and chlamydia when taken every day.
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(95%)
The author makes several statements that are factual and do not contain any logical fallacies. However, there is an instance of an appeal to authority when the author mentions clinical trials suggesting DoxyPEP can protect against a certain percentage of STIs. This does not necessarily mean that the drug will have the same effect on everyone or in all situations.
Two little pills are already having some resounding success.
There have been a handful of clinical trials suggesting DoxyPEP can protect against 70-89% of chlamydia infections and 73-87% of syphilis infections.
